RetinaLyze International

Hjem
Danmark
Skovlunde
RetinaLyze International

Safe, fast and efficient retinal investigations with RetinaLyze AI and Telemedicine.

15/04/2026

It’s interesting to watch how quickly AI in healthcare is changing shape.

Not that long ago, tools like ChatGPT were something people experimented with on the side. Now we’re seeing versions built specifically for healthcare, like ChatGPT Health and Claude for Healthcare, designed to fit into clinical workflows rather than sit outside them.

You can already feel this in practice.

Patients show up having run their symptoms through AI. Sometimes it helps. Sometimes it creates confusion. Either way, it changes the starting point of the conversation.

At the same time, there’s real potential on the clinician side. Documentation, summaries, admin tasks. The kind of work that quietly takes time away from patients is where these tools may actually make a difference.

In eye care, it raises a familiar question.

Where does AI genuinely help, and where do we need to be careful?

Because no matter how these tools evolve, they don’t replace what happens when you’re looking at a retinal image, weighing subtle findings, and deciding what needs attention now and what can wait.

At RetinaLyze, we see this as part of a broader shift. In diagnostics, but also in how information moves between patients and clinicians. And we're just getting started!

13/04/2026

This was a case that stood out.

An optometrist picked up a subtle but concerning change in the macular area on a routine retinal image of the right eye. The 81 year old patient hadn’t seen an ophthalmologist in more than five years, but now presented with reduced vision and clear central distortion on Amsler testing.

Visual acuity was already down to a level where everyday tasks become difficult. The patient described a central defect rather than just blur, which often shifts your thinking away from refractive or media-related causes and more toward macular pathology.

On the image, the macula didn’t look right. There were changes at the level of the retinal pigment epithelium, with RetinaLyze AI marking bleedings that raised suspicion beyond typical age-related changes.

When reviewed through our telemedical backup, the assessment pointed toward wet AMD but with suspicion of neoplasma.

That distinction matters.

While neovascular AMD is far more common, certain presentations can overlap with or mask more serious underlying processes, including choroidal neoplasms. These are rare, but missing them has clear consequences.

The challenge is that they don’t always announce themselves clearly in a single image.

The patient was recommended urgent follow-up with an ophthalmologist within weeks.

Cases like this sit in that grey zone where pattern recognition alone isn’t enough. It’s about noticing when something doesn’t quite fit, and making sure it’s escalated appropriately.

For optometrists, this is often where the real value lies. Not in making the final diagnosis, but in recognising when the patient deserves a second, sometimes urgent, look.

09/04/2026

We’re looking forward to the FirstOptiker Transalpines Forum on April 17 in Innsbruck.

It’s one of those meetings where the conversation stays close to practice.

How new technology, telemedical workflows, and AI-based screening actually fit into everyday clinical work. Not just what’s possible, but what’s usable.

Events like this tend to bring together different perspectives from across optometry and ophthalmology in the DACH region.

If you’re attending, visit Anthonsen and Barbara Anthonsen Wohlgemuth from RetinaLyze DACH!

07/04/2026

Why workflows matter!

Medibrix and RetinaLyze work together to create great customer journeys. Learn more in the video with Teddy and Marius!

01/04/2026

A patient came in with a simple story.

He had bent down to pick something up… and suddenly his vision in one eye became blurred.
Not gone, just off.

Over the next hours, it started to improve, but something still wasn’t right. He described it as grey shadows above and below, while straight ahead seemed clear.

Visual acuity was still 0.8 as the last visit.
It would be easy to downplay.

But when we compared retinal images from a few months earlier, the picture changed. The newer image showed signs consistent with a branch retinal artery occlusion (BRAO).

This is where it gets tricky!

A branch retinal artery occlusion doesn’t always present dramatically. Because only part of the retina is affected, patients can keep relatively good central vision. Instead, they notice subtle field defects, shadows, missing areas, something “not quite right.”

If symptoms improve, there's even more reason it can be overlooked.

On fundus images, you may see a sector of the retina that looks pale or washed out, following the distribution of the affected artery. Sometimes it’s obvious. Sometimes it’s easy to miss. Especially without something to compare it to.

The combination of patient story + imaging + comparison over time is what reveals the real diagnosis.

Cases like this are a good reminder:
Not every serious retinal event comes with poor visual acuity or dramatic symptoms. And not every “improvement” means resolution.

30/03/2026

AI decision support: Raising clinical confidence while saving time - RetinaLyze x

As part of our cooperation with Medibrix, their AI Decision Support brick brings advanced, certified tools directly into the daily routines of optical stores, clinics, and ophthalmology teams.

🔹 Fast, reliable and certified assessments
Fundus photos and OCTs can be analyzed instantly, helping clinicians detect early signs of diabetic retinopathy, AMD, glaucoma, and other retinal conditions.

🔹 An opportunity to expand services
With AI safety nets in place, optometrists can confidently broaden their menu of clinical offerings adding more value for customers and patients.

🔹 A powerful training companion
AI becomes a second set of eyes that helps new clinicians build skills, spot subtle findings, and grow faster in their clinical journey.

Bringing these AI into the Medibrix ecosystem means eye care teams can deliver safer, smarter, and more standardized care without slowing down the workflow.

25/03/2026

Optometry can’t stand still.

Demand for eye care is rising. Complexity is increasing.
And yet, too often, the system still works in silos.

On World Optometry Day 2026, the message from the World Council Of Optometry is clear:

Collaboration is no longer optional!

Optometrists are more than refractionists. They are the front line of detection.
The gatekeepers of early intervention.

And a critical link to ophthalmology and wider healthcare.

At RetinaLyze System A/S, we build for that reality with AI that fits into real workflows, tools that strengthen clinical decision-making and technology that connects, rather than isolates.

Thank you to all the optometrists working with us to improve eye care around the world!

23/03/2026

World Optometry Day is a chance to celebrate the people moving eye care forward!

Not only through patient care, but through collaboration, education, and research.

This year’s World Optometry Week theme from the World Council Of Optometry is “A Shared Vision: Collaboration in Global Eye Care”, celebrated March 22–28, 2026, with World Optometry Day on March 23.

One optometrist who reflects that spirit well is Sarah Farrant. She has built a strong reputation as an expert in therapeutics and dry eye management, has served as President of the BRITISH CONTACT LENS ASSOCIATION LIMITED, spent 12 years on the College of Optometrists council, chaired the Somerset Local Optical Committee, and has been described as instrumental in initiatives that improve both professional education and patient access to eye care.

She also continues to champion academic excellence, curiosity, and responsible use of new technologies in practice.

At RetinaLyze System A/S, we believe progress in eye care happens faster when knowledge is shared and technology helps connect professionals across settings.

Our work is built around supporting collaboration between optometrists, ophthalmologists, clinics, and healthcare systems.

We help make retinal screening more accessible, scalable, and actionable.

Because better outcomes start with a shared vision.

Thank you to all optometrists, researchers, educators, and clinical partners who keep pushing the profession forward.

20/03/2026

What a day at Sociedad Española de Retina y Vítreo in Madrid!

If you haven't already, be sure to visit Bloss Group who will be showcasing RetinaLyze System A/S tomorrow!

AI-powered retinal screening with a special focus on glaucoma progression monitoring.

Stand 8–9

19/03/2026

Going to Sociedad Española de Retina y Vítreo at the Madrid Marriott Auditorium Hotel & Conference Center?

Be sure to visit Bloss Group who will be showcasing RetinaLyze!

AI-powered retinal screening with a special focus on glaucoma progression monitoring!

Learn how our technology helps clinicians detect changes earlier, track disease development over time, and support more precise decision-making in daily practice.

👁️ See you at the 29th SERV Congress in Madrid!
📆 March 20–21 | 📍 Madrid Marriott Auditorium | Stand 8–9

17/03/2026

It’s been a full day on the road for Teddy and Ganesh from RetinaLyze System A/S.

We've been meeting partners, exploring new markets, and having great conversations about the future of eye screening.

One thing is clear:
The demand for smarter, scalable screening solutions is growing fast.

So what does a RetinaLyze partnership actually offer?
• More value from existing devices

Turn every fundus camera into a stronger revenue driver with AI-powered screening workflows.

• Access to new customer segments
Reach opticians, pharmacies, GPs, and telemedicine providers who are entering eye care.

• Stronger device sales
Make your offering more attractive by bundling imaging hardware with AI-driven diagnostics.

• Recurring revenue streams
Move beyond one-time sales with usage-based income tied to every screening performed.

In short:
We help you sell more, reach further, and build long-term value.
We’re actively looking for distribution partners ready to grow with us.

Interested?
Let’s talk → info@retinalyze.com

16/03/2026

Can a 2D fundus image reveal the third dimension?

At opti 2026 in Munich, we introduced our new glaucoma AI algorithm from RetinaLyze International. The response sparked an idea: this needs a proper online demonstration.

Now it’s happening.

Together with the partnerauge GmbH, and eyebizz, RetinaLyze DACH is hosting a free live webinar on March 17 at 10:00 titled:

“Zukunft der Augengesundheitsversorgung in die richtigen Bahnen lenken”

During the session we will demonstrate how 3D information can be derived from standard 2D fundus images and what this could mean for glaucoma screening and early detection in optometric practice.

We will also briefly share some of the other solutions and updates presented at opti 2026.

Another highlight:
Svenja Dominique Kim, who recently joined the RetinaLyze team, will take part in a short interview about a topic many in the industry are discussing:

Why optometrists and optical stores are - and should remain - the first point of contact in eye health screening.

If you work in optometry, ophthalmology, or eye care technology, this session will give a practical look at where screening tools are heading.

Register here (free):
https://us02web.zoom.us/webinar/register/5317732301510/WN_7DSMoPWmTGmYKL3xZQASgg #/registration

Adresse

Lyskær 1
Skovlunde
2730

Hvad er åbningstiderne?

Mandag	09:00 - 17:30
Tirsdag	09:00 - 17:30
Onsdag	09:00 - 17:30
Torsdag	09:00 - 17:30
Fredag	09:00 - 17:30

Internet side

https://retinalyze.com/

Underretninger

Vær den første til at vide, og lad os sende dig en email, når RetinaLyze International sender nyheder og tilbud. Din e-mail-adresse vil ikke blive brugt til andre formål, og du kan til enhver tid afmelde dig.

Kontakt Praksis

Send en besked til RetinaLyze International:

Genveje

Vil du plassere din praksis på toppen av Klinik-listen i Skovlunde?

Del

Prevention of blindness through AI

RetinaLyze prevents loss of eyesight by making eye screening accessible. 80% of all blindness is preventable. Early screening and diagnosis is crucial and possible with Retinalyze' automated retinal screening tools and telemedicine solutions. Our mission is to make it easier for people all over the world to have their eyes tested and prevent the tragic consequences caused by late treatment of retinal lesions.

RetinaLyze® is a screening software, which helps eye care professionals perform screenings for eye diseases in a safe and efficient manner. The automated algorithm (AI) module detects eye diseases by analyzing fundus images. It can be used as a clinical decision support system (CDSS) or as a screening tool in conjunction with the telemedicine module. Retinalyze System A/S is a registered company in Denmark. Check us out at https://RetinaLyze.com.